ESR1 and breast carcinoma: The PCL–HAP–nano-clay model was also used with patient-derived breast cancer estrogen-receptor-positive (ER+) and triple-negative (TN) breast cancer tissues to study osteolytic and osteoblastic implications of breast cancer on bone [70] as well as evaluate drug efficacies [73].